[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

ME02873B - Pirimidini kao blokatori natrijumskog kanala - Google Patents

Pirimidini kao blokatori natrijumskog kanala

Info

Publication number
ME02873B
ME02873B MEP-2017-219A MEP2017219A ME02873B ME 02873 B ME02873 B ME 02873B ME P2017219 A MEP2017219 A ME P2017219A ME 02873 B ME02873 B ME 02873B
Authority
ME
Montenegro
Prior art keywords
pyrimidines
sodium channel
channel blockers
blockers
sodium
Prior art date
Application number
MEP-2017-219A
Other languages
German (de)
English (en)
French (fr)
Inventor
Chiyou Ni
Minnie Park
Bin Shao
Laykea Tafesse
Jiangchao Yao
Mark Youngman
Original Assignee
Purdue Pharma Lp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Purdue Pharma Lp filed Critical Purdue Pharma Lp
Publication of ME02873B publication Critical patent/ME02873B/me

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MEP-2017-219A 2011-09-02 2012-08-31 Pirimidini kao blokatori natrijumskog kanala ME02873B (me)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161530678P 2011-09-02 2011-09-02
US201261651611P 2012-05-25 2012-05-25
EP12770217.3A EP2753606B1 (en) 2011-09-02 2012-08-31 Pyrimidines as sodium channel blockers
PCT/IB2012/001871 WO2013030665A1 (en) 2011-09-02 2012-08-31 Pyrimidines as sodium channel blockers

Publications (1)

Publication Number Publication Date
ME02873B true ME02873B (me) 2018-04-20

Family

ID=47010645

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-2017-219A ME02873B (me) 2011-09-02 2012-08-31 Pirimidini kao blokatori natrijumskog kanala

Country Status (19)

Country Link
US (4) US9163008B2 (me)
EP (2) EP2753606B1 (me)
JP (2) JP5941546B2 (me)
AR (1) AR088029A1 (me)
AU (1) AU2012300567B2 (me)
CA (1) CA2846463C (me)
CY (1) CY1119327T1 (me)
DK (1) DK2753606T3 (me)
ES (1) ES2643235T3 (me)
HR (1) HRP20171389T1 (me)
HU (1) HUE034925T2 (me)
LT (1) LT2753606T (me)
ME (1) ME02873B (me)
PL (1) PL2753606T3 (me)
PT (1) PT2753606T (me)
RS (1) RS56342B1 (me)
SI (1) SI2753606T1 (me)
TW (1) TW201331186A (me)
WO (1) WO2013030665A1 (me)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013530180A (ja) 2010-06-16 2013-07-25 パーデュー、ファーマ、リミテッド、パートナーシップ アリール置換インドールおよびその使用
JP2013531687A (ja) 2010-07-16 2013-08-08 パーデュー、ファーマ、リミテッド、パートナーシップ ナトリウムチャネル遮断剤としてのピリジン化合物
EP3590925B1 (en) 2010-09-17 2022-03-30 Purdue Pharma L.P. Pyridine compounds and the uses thereof
ES2540562T3 (es) 2010-10-05 2015-07-10 Purdue Pharma L.P. Compuestos de quinazolina como bloqueadores de canales de sodio
WO2012085650A1 (en) 2010-12-22 2012-06-28 Purdue Pharma L.P. Substituted pyridines as sodium channel blockers
US9163008B2 (en) 2011-09-02 2015-10-20 Purdue Pharma, L.P. Pyrimidines as sodium channel blockers
US9181185B2 (en) 2011-10-31 2015-11-10 Purdue Pharma L.P. Heteroaryl compounds as sodium channel blockers
AU2012321111A1 (en) 2011-10-31 2013-05-16 Purdue Pharma L.P. Quaternized amines as sodium channel blockers
WO2013072758A1 (en) 2011-11-15 2013-05-23 Purdue Pharma L.P. Pyrimidine diol amides as sodium channel blockers
US9206127B2 (en) 2012-03-16 2015-12-08 Purdue Pharm, L.P. Substituted pyridines as sodium channel blockers
JP6400592B2 (ja) 2012-11-09 2018-10-03 パーデュー、ファーマ、リミテッド、パートナーシップ ベンゾモルファン類似体およびその使用
WO2014096941A1 (en) 2012-12-20 2014-06-26 Purdue Pharma L.P. Cyclic sulfonamides as sodium channel blockers
ES2680246T3 (es) 2013-03-04 2018-09-05 Purdue Pharma Lp Pirimidincarboxamidas como bloqueantes de canal de sodio
US9120786B2 (en) 2013-03-04 2015-09-01 Purdue Pharma, L.P. Triazine carboxamides as sodium channel blockers
AU2014235063B2 (en) * 2013-03-15 2017-05-04 Purdue Pharma L.P. Carboxamide derivatives and use thereof
FI3421462T3 (fi) * 2013-06-27 2023-06-26 Pfizer Heteroaromaattisia yhdisteitä ja niiden käyttö dopamiini-d1-ligandeina
WO2015031036A1 (en) 2013-08-26 2015-03-05 Purdue Pharma L.P. Azaspiro[4.5] decane derivatives and use thereof
US9359330B2 (en) * 2013-08-26 2016-06-07 Purdue Pharma L.P. Substituted piperidines as sodium channel blockers
AU2014340318B2 (en) * 2013-10-21 2019-01-17 Merck Patent Gmbh Heteroaryl compounds as BTK inhibitors and uses thereof
US9828348B2 (en) 2013-11-08 2017-11-28 Purdue Pharma L.P. Benzimidazole derivatives and use thereof
US9340504B2 (en) 2013-11-21 2016-05-17 Purdue Pharma L.P. Pyridine and piperidine derivatives as novel sodium channel blockers
NZ760006A (en) 2013-12-13 2022-07-29 Vertex Pharma Prodrugs of pyridone amides useful as modulators of sodium channels
EP3083606B1 (en) 2013-12-20 2020-10-28 Purdue Pharma LP Pyrimidines and use thereof
AU2014370407B2 (en) * 2013-12-23 2018-03-29 Purdue Pharma L.P. Indazoles and use thereof
US9695144B2 (en) 2013-12-23 2017-07-04 Purdue Pharma L.P. Dibenzazepine derivatives and use thereof
US9902726B2 (en) 2013-12-30 2018-02-27 Purdue Pharma L.P. Pyridone-sulfone morphinan analogs as opioid receptor ligands
CN106061944A (zh) 2014-01-24 2016-10-26 普渡制药公司 吡啶类和嘧啶类物质及其用途
CA2939501C (en) 2014-02-12 2020-07-07 Purdue Pharma L.P. Isoquinoline derivatives and use thereof
US10730866B2 (en) 2014-04-07 2020-08-04 Purdue Pharma L.P. Indole derivatives and use thereof
US9975854B2 (en) 2014-05-06 2018-05-22 Purdue Pharma L.P. Benzomorphan analogs and use thereof
US10131666B2 (en) 2014-06-13 2018-11-20 Purdue Pharma L.P. Heterocyclic morphinan derivatives and use thereof
MA40171A (fr) 2014-06-13 2017-04-19 Purdue Pharma Lp Dérivés d'azamophinan et leur utilisation
JP6762308B2 (ja) * 2015-02-19 2020-09-30 パーデュー、ファーマ、リミテッド、パートナーシップ 胃排出の減少方法及び組成物
WO2018125716A1 (en) 2017-01-02 2018-07-05 Purdue Pharma L.P. Morphinan derivatives and use thereof
UA124857C2 (uk) 2017-05-16 2021-12-01 Вертекс Фармасьютикалз Інкорпорейтед Дейтеровані піридонаміди і їх проліки як модулятори натрієвих каналів
JP7114394B2 (ja) * 2017-08-18 2022-08-08 住友化学株式会社 化合物、レジスト組成物及びレジストパターンの製造方法
TW202002971A (zh) 2018-02-12 2020-01-16 美商維泰克斯製藥公司 治療疼痛的方法

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL260746A (me) * 1960-02-02
WO1996041626A1 (en) 1995-06-12 1996-12-27 G.D. Searle & Co. Compositions comprising a cyclooxygenase-2 inhibitor and a 5-lipoxygenase inhibitor
US5739127A (en) * 1996-11-08 1998-04-14 Bayer Aktiengesellschaft 2,4'-bridged bis-2,4-diaminoquinazolines
IL132522A0 (en) 1997-04-22 2001-03-19 Cocensys Inc Carbocyclic and heterocyclic substituted semicarbazones and thiosemicarbazones and pharmaceutical compositions containing the same
WO1999026614A1 (en) 1997-11-21 1999-06-03 Euro-Celtique S.A. Substituted 2-aminoacetamides and the use thereof
US6281211B1 (en) 1999-02-04 2001-08-28 Euro-Celtique S.A. Substituted semicarbazides and the use thereof
CN1353605A (zh) 1999-03-26 2002-06-12 欧洲凯尔特股份有限公司 芳基取代的吡唑、咪唑、噁唑、噻唑和吡咯及其应用
CA2370030C (en) 1999-04-09 2007-08-14 Euro-Celtique S.A. Sodium channel blocker compositions and the use thereof
AR029489A1 (es) 2000-03-10 2003-07-02 Euro Celtique Sa Piridinas, pirimidinas, pirazinas, triazinas sustituidas por arilo, composiciones farmaceuticas y el uso de las mismas para la manufactura de un medicamento
US7078426B2 (en) 2000-03-24 2006-07-18 Euro-Celtique S.A. Aryl substituted pyrazoles, triazoles, and tetrazoles, and the use thereof
EP1268427A1 (en) 2000-03-31 2003-01-02 Cocensys, Inc. Aminopyridines and their use as anticonvulsants and sodium channel blockers
CA2453633A1 (en) 2001-07-16 2003-01-30 Euro-Celtique S.A. Aryl substituted thiazolidinones and the use thereof
AR037233A1 (es) 2001-09-07 2004-11-03 Euro Celtique Sa Piridinas aril sustituidas, composiciones farmaceuticas y el uso de dichos compuestos para la elaboracion de un medicamento
AR036873A1 (es) 2001-09-07 2004-10-13 Euro Celtique Sa Piridinas aril sustituidas a, composiciones farmaceuticas y el uso de las mismas para la preparacion de un medicamento
ATE355064T1 (de) * 2001-10-26 2006-03-15 Angeletti P Ist Richerche Bio Dihydroxypyrimidin-carbonsäueramid-hemmer der hiv-integrase
TWI329105B (en) * 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
CN1646500A (zh) 2002-03-13 2005-07-27 欧洲凯尔特股份有限公司 芳基取代的嘧啶及其用途
AU2003220184A1 (en) * 2002-03-20 2003-10-08 Schering Aktiengesellschaft Substituted piperazine antithrombotic pai-1 inhibitors
US6675042B2 (en) 2002-04-15 2004-01-06 Charles D. Swerdlow Defibrillation shock strength determination technology
CN1671672A (zh) 2002-07-31 2005-09-21 欧洲凯尔特股份有限公司 芳基取代的苯并咪唑类及其作为钠通道阻滞剂的用途
WO2004010950A2 (en) 2002-07-31 2004-02-05 Euro-Celtique S.A. Aryl substituted hydantoin compounds and their use as sodium channel blockers
US20040152696A1 (en) 2002-08-01 2004-08-05 Euro-Celtique S.A. 2-substituted bicyclic benzoheterocyclic compounds and their use as sodium channel blockers
PT2316831E (pt) * 2002-11-21 2013-06-06 Novartis Ag 2-(morfolin-4-il)pirimidinas como inibidores da fosfatidilinositol (pi) quinase e a sua utilização no tratamento do cancro
JP4666256B2 (ja) * 2002-12-10 2011-04-06 小野薬品工業株式会社 含窒素複素環化合物およびその医薬用途
CN1791580A (zh) * 2003-03-24 2006-06-21 麦克公司 联芳基取代的6元杂环钠通道阻滞剂
EP1644338A1 (en) * 2003-04-01 2006-04-12 Aponetics AG 2, 4, 6-trisubstituted pyrimidine derivatives useful for the treatment of neoplastic and autoimmune diseases
WO2005014849A2 (en) 2003-07-03 2005-02-17 Euro-Celtique, S.A. Genes associated with responses to neuropathic pain
TWI355894B (en) * 2003-12-19 2012-01-11 Du Pont Herbicidal pyrimidines
WO2005113514A2 (en) 2004-05-07 2005-12-01 Janssen Pharmaceutica, N.V. Substituted pyrimidines as inhibitors of bacterial type iii protein secretion systems
EP1652831A4 (en) 2004-06-25 2009-07-01 Ibiden Co Ltd PROCESS FOR PRODUCING POROUS BODIES, POROUS BODIES, AND ALVEOLAR STRUCTURAL BODY
TW200616974A (en) 2004-07-01 2006-06-01 Astrazeneca Ab Chemical compounds
JP2008519034A (ja) * 2004-11-03 2008-06-05 バーテックス ファーマシューティカルズ インコーポレイテッド イオンチャネル調節剤としてのピリミジン誘導体および使用方法
TW200640877A (en) 2005-04-28 2006-12-01 Actelion Pharmaceuticals Ltd Pyrimidine derivatives
ATE533749T1 (de) 2005-05-24 2011-12-15 Vertex Pharma Modulatoren von atp-bindenden kassettentransportern
WO2007013691A1 (ja) * 2005-07-29 2007-02-01 Takeda Pharmaceutical Company Limited スピロ環化合物
WO2007089382A2 (en) 2006-01-03 2007-08-09 Pharmagic, Inc. Nanofactory compositions and methods of making and using nanofactories
KR20080083188A (ko) * 2006-01-11 2008-09-16 아스트라제네카 아베 모르폴리노 피리미딘 유도체 및 요법에서의 그 유도체의용도
WO2008023159A1 (en) * 2006-08-24 2008-02-28 Astrazeneca Ab Morpholino pyrimidine derivatives useful in the treatment of proliferative disorders
EP2146981A1 (en) * 2007-04-12 2010-01-27 F. Hoffmann-Roche AG Pharmaceutical compounds
KR20100042643A (ko) * 2007-07-09 2010-04-26 아스트라제네카 아베 증식성 질환을 치료하기 위한 삼중치환된 피리미딘 유도체
WO2009066084A1 (en) * 2007-11-21 2009-05-28 F. Hoffmann-La Roche Ag 2 -morpholinopyrimidines and their use as pi3 kinase inhibitors
EP2326640A1 (en) * 2008-07-30 2011-06-01 Ranbaxy Laboratories Limited Pyrrole carboxylic acid derivatives as antibacterial agents
ES2412780T3 (es) * 2008-09-10 2013-07-12 Mitsubishi Tanabe Pharma Corporation Compuestos aromáticos de anillo de 6 miembros que contiene nitrógeno y su uso
CA2783209C (en) 2009-12-22 2017-03-14 Msd Oss B.V. Amino-heteroaryl derivatives as hcn blockers
BR112012015827A2 (pt) * 2009-12-28 2016-12-06 Dcb Usa Llc novos compostos de pirimidina como inibidores de mtor e p13k
AU2011218167B2 (en) * 2010-02-17 2014-07-10 Amgen Inc. Aryl carboxamide derivatives as sodium channel inhibitors for treatment of pain
EP2382865A1 (de) 2010-04-28 2011-11-02 Bayer CropScience AG Synergistische Wirkstoffkombinationen
US8877745B2 (en) * 2010-05-12 2014-11-04 Boehringer Ingelheim International Gmbh CCR2 receptor antagonists, method for producing the same, and use thereof as medicaments
JP2013530180A (ja) 2010-06-16 2013-07-25 パーデュー、ファーマ、リミテッド、パートナーシップ アリール置換インドールおよびその使用
JP2013531687A (ja) 2010-07-16 2013-08-08 パーデュー、ファーマ、リミテッド、パートナーシップ ナトリウムチャネル遮断剤としてのピリジン化合物
EP3590925B1 (en) 2010-09-17 2022-03-30 Purdue Pharma L.P. Pyridine compounds and the uses thereof
ES2540562T3 (es) 2010-10-05 2015-07-10 Purdue Pharma L.P. Compuestos de quinazolina como bloqueadores de canales de sodio
GB201112607D0 (en) * 2011-07-22 2011-09-07 Glaxo Group Ltd Novel compounds
US8933085B2 (en) * 2010-11-19 2015-01-13 Incyte Corporation Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors
WO2012085650A1 (en) 2010-12-22 2012-06-28 Purdue Pharma L.P. Substituted pyridines as sodium channel blockers
JP5786258B2 (ja) * 2011-07-15 2015-09-30 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規かつ選択的なｃｃｒ２拮抗薬
US9163008B2 (en) 2011-09-02 2015-10-20 Purdue Pharma, L.P. Pyrimidines as sodium channel blockers
AU2012321111A1 (en) 2011-10-31 2013-05-16 Purdue Pharma L.P. Quaternized amines as sodium channel blockers
US9181185B2 (en) 2011-10-31 2015-11-10 Purdue Pharma L.P. Heteroaryl compounds as sodium channel blockers
WO2013072758A1 (en) 2011-11-15 2013-05-23 Purdue Pharma L.P. Pyrimidine diol amides as sodium channel blockers
US9206127B2 (en) 2012-03-16 2015-12-08 Purdue Pharm, L.P. Substituted pyridines as sodium channel blockers
US9718865B2 (en) 2012-07-27 2017-08-01 Purdue Pharma L.P. Sodium channel blocking peptides and the use thereof
WO2014096941A1 (en) 2012-12-20 2014-06-26 Purdue Pharma L.P. Cyclic sulfonamides as sodium channel blockers
ES2680246T3 (es) * 2013-03-04 2018-09-05 Purdue Pharma Lp Pirimidincarboxamidas como bloqueantes de canal de sodio
US9120786B2 (en) 2013-03-04 2015-09-01 Purdue Pharma, L.P. Triazine carboxamides as sodium channel blockers
AU2014235063B2 (en) * 2013-03-15 2017-05-04 Purdue Pharma L.P. Carboxamide derivatives and use thereof
US9346802B2 (en) * 2013-03-15 2016-05-24 Epizyme, Inc. CARM1 inhibitors and uses thereof
SG11201507070XA (en) * 2013-03-15 2015-10-29 Epizyme Inc Carm1 inhibitors and uses thereof
WO2015031036A1 (en) 2013-08-26 2015-03-05 Purdue Pharma L.P. Azaspiro[4.5] decane derivatives and use thereof
US9359330B2 (en) 2013-08-26 2016-06-07 Purdue Pharma L.P. Substituted piperidines as sodium channel blockers
US9340504B2 (en) 2013-11-21 2016-05-17 Purdue Pharma L.P. Pyridine and piperidine derivatives as novel sodium channel blockers
EP3083606B1 (en) 2013-12-20 2020-10-28 Purdue Pharma LP Pyrimidines and use thereof
AU2014370407B2 (en) * 2013-12-23 2018-03-29 Purdue Pharma L.P. Indazoles and use thereof
US10730866B2 (en) 2014-04-07 2020-08-04 Purdue Pharma L.P. Indole derivatives and use thereof
JP6762308B2 (ja) 2015-02-19 2020-09-30 パーデュー、ファーマ、リミテッド、パートナーシップ 胃排出の減少方法及び組成物

Also Published As

Publication number Publication date
US9656968B2 (en) 2017-05-23
US20190002412A1 (en) 2019-01-03
SI2753606T1 (sl) 2017-10-30
HUE034925T2 (en) 2018-03-28
ES2643235T3 (es) 2017-11-21
JP2016175940A (ja) 2016-10-06
EP2753606A1 (en) 2014-07-16
US20160024022A1 (en) 2016-01-28
DK2753606T3 (en) 2017-10-02
CY1119327T1 (el) 2018-02-14
US20140303139A1 (en) 2014-10-09
CA2846463C (en) 2017-10-24
TW201331186A (zh) 2013-08-01
AU2012300567A1 (en) 2013-05-02
PT2753606T (pt) 2017-10-02
PL2753606T3 (pl) 2018-02-28
US10059675B2 (en) 2018-08-28
AU2012300567B2 (en) 2016-03-10
LT2753606T (lt) 2017-09-25
WO2013030665A1 (en) 2013-03-07
US20170298027A1 (en) 2017-10-19
EP3255041A1 (en) 2017-12-13
JP6239688B2 (ja) 2017-11-29
JP5941546B2 (ja) 2016-06-29
HRP20171389T1 (hr) 2017-11-03
US9163008B2 (en) 2015-10-20
CA2846463A1 (en) 2013-03-07
RS56342B1 (sr) 2017-12-29
EP2753606B1 (en) 2017-07-05
AR088029A1 (es) 2014-05-07
JP2014525431A (ja) 2014-09-29
US10774050B2 (en) 2020-09-15

Similar Documents

Publication Publication Date Title
HRP20171389T1 (hr) Pirimidini kao blokatori natrijevog kanala
ZA201303780B (en) Substituted pyridines as sodium channel blockers
IL225516A0 (en) Quinazoline compounds as sodium channel blockers
ZA201205126B (en) Voltage-gated sodium channel blockers
EP2711605A4 (en) LAMP
HK1200114A1 (en) Sodium channel blockers reduce glucagon secretion
GB201400060D0 (en) Enhancing communication
EP2795187A4 (en) LIGHT GUIDE FOR LUMINAIRE
HK1184599A1 (zh) 光下行鏈路系統
IL229447B (en) History of amine as potassium channel blockers
IL229410A0 (en) Metabolized pyridopyrazines as novel cyk inhibitors
EP2661179A4 (en) COMPOSITION WITH REDUCED SODIUM CONTENT
EP2669731A4 (en) GLASSES
GB201102129D0 (en) Recessed light fitting
AU339253S (en) Light
EP2758058A4 (en) SUBSTITUTED PYRIMIDINES
PT2780295E (pt) Vidraça hidrófoba
EP2758059A4 (en) SUBSTITUTED PYRIMIDINES
GB2497151B (en) Multipoint communications
ZA201309533B (en) Voltage-gated sodium channel blockers
EP2696519A4 (en) OPTICAL RECEIVER
ZA201402298B (en) Heterocyclylpyri (mi)dinylpyrazole as fungicidals
PL2518249T3 (pl) Zespół oszklenia
GB201120262D0 (en) Simultaneous demultiplexing
GB2496315B (en) Multiplex optical assembly